Taking targeted drugs after surgery for endometrioid adenocarcinoma has certain therapeutic effect and can improve the survival period, but it is difficult to achieve complete cure.
Endometrioid adenocarcinoma is a kind of malignant tumor occurring in the endometrium, most common in postmenopausal women and perimenopausal women. After diagnosis, if there are surgical indications, surgery can be performed as early as possible for treatment, and targeted therapy can be used after surgery.
After surgery, targeted therapy can be used. Targeted therapy is mainly carried out through estrogen signaling inhibitors, such as epidermal growth factor receptor inhibitors, trastuzumab and other drugs, which can improve the prognosis of endometrial cancer and prolong the survival period of patients. The use of the above drugs should follow the doctor’s prescription and should not be used without authorization.
For patients with endometrial cancer, early detection and early treatment are recommended, and they should consult the gynecology department of regular hospitals.